Qi Biodesign builds and commercializes a proprietary SEEDIT™ research platform that includes novel RNA‑guided nucleases, base editors, plant prime editors, and PrimeRoot™ editors for precise large DNA insertions and multiplex trait engineering. Its tools enable multiplex gene editing, fine‑tuning of gene expression, high‑throughput trait discovery, and acceleration of superior trait development for crops and synthetic biology applications. The company has achieved regulatory milestones, including two biosafety certificates from the China Ministry of Agriculture and Rural Affairs for high oleic acid soybean and powdery mildew‑resistant wheat, and an exemption from the U.S. Department of Agriculture for its high oleic acid soybean. Qi Biodesign is advancing additional traits—yield, herbicide tolerance, and quality improvements—through regulatory pipelines. The company plans to use new funding to enhance R&D, advance SEEDIT™, support product development, and build commercialization platforms to speed transition from research to market. Founded by genome‑editing scientists and industry executives, Qi Biodesign positions its platform to address food security and sustainable agriculture challenges.

Total raised

$75M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2024